We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Neurology

Disability Dynamics Independent of Attacks in AQP4-IgG+ NMOSD and MOGAD: Insights from a Multicenter Cohort Study

MedXY Editorial Team•Jul 3, 2026•Neurology
AQP4-IgG+ NMOSDattack-independent progressiondisability improvementdisability worseningMOGAD

Highlight

  • Confirmed disability improvement (CDI) and confirmed disability worsening (CDW) independent of attacks occur in both AQP4-IgG+ NMOSD and MOGAD patients, albeit infrequently.
  • Lower prior attack number correlates with higher CDI rates in AQP4-IgG+ NMOSD, underscoring the importance of early attack prevention.
  • Younger patient age is associated with increased chances of disability improvement in both diseases.
  • Annualized CDI and CDW rates are comparable between AQP4-IgG+ NMOSD and MOGAD.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Early Escalation of Acute Treatment Reduces Relapse Risk in Pediatric MOG Antibody-Associated DiseaseIn pediatric myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), escalation of acute immunotherapy beyond steroids at first attack is linked to significantly fewer relapses within one year and mid-term follow-up, highliAug 25, 2026Interleukin 6 Receptor Blockade: A Promising Strategy for Relapse Prevention in MOG Antibody-Associated DiseaseIL-6 receptor blockade significantly reduces relapse rates in MOG antibody-associated disease, showing comparable efficacy to high-dose IVIG with a favorable safety profile, supporting its role in relapse prevention.Jul 16, 2026French Registry Data Show Marked Declines in Relapse Activity and Faster Diagnosis in AQP4+NMOSD and MOGAD From 2010 to 2024A nationwide French cohort found earlier diagnosis, falling relapse rates, and major treatment shifts in AQP4+NMOSD and MOGAD, with rituximab linked to lower disability risk in AQP4+NMOSD and overall milder disability trajectories in MOGAD.May 26, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Treatment Discontinuation in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
In adults with MOGAD, stopping maintenance therapy was associated with a low 1-year relapse risk, especially after longer treatment and a longer relapse-free interval. The findings support individualized decisions and close follow-up after
May 13, 2026
Why the New MS Diagnostic Criteria Require Caution: High Frequency of MOGAD and NMOSD in Optic Neuritis PatientsA retrospective study reveals that 24% of patients meeting the latest MS criteria following optic neuritis actually have MOGAD or NMOSD, emphasizing the need for antibody testing to prevent misdiagnosis.Mar 30, 2026
Navigating the Diagnostic Overlap: Why 24 Percent of Patients Meeting Minimal MS Criteria for Optic Neuritis Require Antibody TestingA multicenter study reveals that nearly one-quarter of patients meeting the newest multiple sclerosis criteria for optic neuritis actually have MOGAD or NMOSD, emphasizing the critical role of antibody screening and detailed orbital MRI in Mar 18, 2026